Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov sold 10,000 shares of the company's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of C$10.66, for a total transaction of C$106,586.00.
Rostislav Christov Raykov also recently made the following trade(s):
- On Friday, May 16th, Rostislav Christov Raykov sold 16,667 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$9.49, for a total transaction of C$158,203.16.
- On Friday, April 4th, Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$7.46, for a total value of C$74,550.00.
Fennec Pharmaceuticals Stock Performance
Fennec Pharmaceuticals stock traded down C$0.40 during mid-day trading on Wednesday, reaching C$11.15. 704 shares of the company's stock were exchanged, compared to its average volume of 1,164. The business's fifty day simple moving average is C$8.91 and its 200 day simple moving average is C$8.99. The firm has a market capitalization of C$215.02 million, a PE ratio of -188.88 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a one year low of C$5.65 and a one year high of C$12.11. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Recommended Stories
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
